News
November 08, 2025
Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine
Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy
**Brii Biosciences Sheds Light on HBV Functional Cure with Promising Phase 2 ENSURE Study Results**
DURHAM, NC – Brii Biosciences, a multi-national company committed to developing innovative therapies for diseases with significant unmet needs, has announced the publication of the results from its Phase 2 ENSURE study in the prestigious journal, Nature Medicine. The findings offer valuable scientific insights into a potential pathway toward achieving a functional cure for chronic Hepatitis B virus (HBV) infection, a global health challenge affecting millions.
The ENSURE study investigated the combined approach of using small interfering RNA (siRNA) and therapeutic vaccination as a strategy to combat HBV. Chronic HBV infection occurs when the body's immune system is unable to clear the virus, leading to long-term liver damage and an increased risk of cirrhosis and liver cancer. A functional cure, unlike a complete viral eradication, aims to suppress the virus to undetectable levels in the blood, even after treatment stops, allowing patients to live without continuous antiviral medication.
The study focused on evaluating how siRNA and therapeutic vaccination could work synergistically to achieve this functional cure. SiRNA works by specifically targeting and silencing viral RNA, effectively reducing the production of new viral particles. Therapeutic vaccination, on the other hand, aims to stimulate the patient's own immune system to recognize and attack the remaining virus, providing long-term control.
The results published in Nature Medicine highlight the potential benefits of this combined approach. The ENSURE study provides critical data on how the two therapies interact and contribute to viral suppression and immune activation. While the specific details of the results are complex and require expert interpretation, the publication in Nature Medicine signifies the importance and rigor of the research conducted by Brii Biosciences.
This publication marks a significant step forward in the ongoing quest for a functional cure for HBV. By providing detailed scientific insights into the mechanisms of action of siRNA and therapeutic vaccination, the ENSURE study lays the groundwork for future research and development efforts aimed at improving treatment options for individuals living with chronic HBV infection. The company hopes that these findings will inspire further innovation and collaboration within the scientific community to ultimately bring a functional cure within reach for patients worldwide.
DURHAM, NC – Brii Biosciences, a multi-national company committed to developing innovative therapies for diseases with significant unmet needs, has announced the publication of the results from its Phase 2 ENSURE study in the prestigious journal, Nature Medicine. The findings offer valuable scientific insights into a potential pathway toward achieving a functional cure for chronic Hepatitis B virus (HBV) infection, a global health challenge affecting millions.
The ENSURE study investigated the combined approach of using small interfering RNA (siRNA) and therapeutic vaccination as a strategy to combat HBV. Chronic HBV infection occurs when the body's immune system is unable to clear the virus, leading to long-term liver damage and an increased risk of cirrhosis and liver cancer. A functional cure, unlike a complete viral eradication, aims to suppress the virus to undetectable levels in the blood, even after treatment stops, allowing patients to live without continuous antiviral medication.
The study focused on evaluating how siRNA and therapeutic vaccination could work synergistically to achieve this functional cure. SiRNA works by specifically targeting and silencing viral RNA, effectively reducing the production of new viral particles. Therapeutic vaccination, on the other hand, aims to stimulate the patient's own immune system to recognize and attack the remaining virus, providing long-term control.
The results published in Nature Medicine highlight the potential benefits of this combined approach. The ENSURE study provides critical data on how the two therapies interact and contribute to viral suppression and immune activation. While the specific details of the results are complex and require expert interpretation, the publication in Nature Medicine signifies the importance and rigor of the research conducted by Brii Biosciences.
This publication marks a significant step forward in the ongoing quest for a functional cure for HBV. By providing detailed scientific insights into the mechanisms of action of siRNA and therapeutic vaccination, the ENSURE study lays the groundwork for future research and development efforts aimed at improving treatment options for individuals living with chronic HBV infection. The company hopes that these findings will inspire further innovation and collaboration within the scientific community to ultimately bring a functional cure within reach for patients worldwide.
Category:
Politics